Our objective was to evaluate the action of topical nasal steroid in nasal congestion and nasal hyper-reactivity in children and adolescents with persistent allergic rhinitis.
Methods
Twenty atopic children and adolescents (6 to 18 years) with moderate-to-severe persistent allergic rhinitis (PAR) were treated with mometasone furoate (100 μg once a day) for 21 days. At the beginning and end of treatment, the following were recorded: a) nasal symptoms score; b) several parameters of nasal congestion measured by acoustic rhinometry (SRE 2000 Rhinometrics); c) degree of nasal hyper-reactivity to histamine (concentration of histamine necessary to induce at least 100% increase in total nasal resistance during nasal provocation test). Data were compared with those from 20 controls.
Results
Compared to controls, PAR patients had significantly higher score of symptoms, as well as higher degree of nasal hyper-reactivity and lower nasal volumes. After treatment, there was a significant decrease in the mean nasal symptoms score (8.0 versus 3.8; p < 0.001) and in the nasal hyper-reactivity (histamine concentration: 0.72 mg/ml versus 2.60 mg/ml; p < 0.001). Congestion improvement was observed by the increase in all acoustic rhinometry parameters. Among all studied volumes, the volume in the segment between 2 and 5 cm showed the highest mean increase (19.8%).
Conclusions
Treatment with topical nasal steroid objectively reduced nasal congestion and nasal histamine hyper-reactivity in children and adolescents with PAR.
MeltzerE., OrgelH., BronskyE.. A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology.J Allergy Clin Immunol86: 221–230, 1990.
2.
DaviesR., and NelsonH.. Once-daily mometasone furoate nasal spray: Efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis.Clin Ther19: 27–38, 1997.
3.
MeltzerE., JalowayskiA., OrgelA., and HarrisA.. Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray.J Allergy Clin Immunol102: 39–49, 1998.
4.
BousquetJ., KhaltaevN., CruzA.. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update.Allergy63(suppl 86): 8–160, 2008.
5.
van CauwenbergeP., BachertC., PassalacquaG.. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology.Allergy55: 16–134, 2000.
6.
WeinerJ., AbramsonM., and PuyR.. Intranasal corticosteroids versus oral H1 receptor in allergic rhinitis: Systematic review of randomized controlled trials.BMJ317: 1624–1629, 1998.
7.
BrannanM., HerronJ., and AffrimeM.. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children.Clin Ther19: 1330–1339, 1997.
8.
MandlM., NolopK., and LutskyB.. Comparison of once daily mometasone furoate and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis.Ann Allergy Asthma Immunol79: 370–378, 1997.
9.
van SpronsenE., IngelsK., JansenA.. Evidence-based recommendations regarding the differential diagnosis and assessment of nasal congestion: using the new GRADE system.Allergy63: 820–833, 2008.
ClementP., and GordtsF.. Consensus report on acoustic rhinometry and rhinomanometry.Rhinology43: 169–179, 2005.
12.
UnnoT., NaitohY., SakamotoN., and HoriganaH.. Nasal resistance measured by anterior rhinomanometry.Rhinology24: 49–55, 1986.
13.
NathanR.. The pathophysiology, clinical impact, and management of nasal congestion in allergic rhinitis.Clin Ther30: 573–586, 2008.
14.
SchatzM.. A survey of the burden of allergic rhinitis in the USA.Allergy62(suppl 85): 9–16, 2007.
15.
HilbergO., JacksonA., SwiftD., and PedersenO.. Acoustic rhinometry: Evaluation of nasal cavity geometry by acoustic reflection.J Appl Physiol66: 295–303, 1989.
16.
TerheydenH., MauneS., MertensJ., and HilbergO.. Acoustic rhinometry: Validation by three-dimensionally reconstructed computer tomographic scans.J Appl Physiol89: 1013–1021, 2000.
17.
HilbergO.. Objective measurement of nasal airway dimensions using acoustic rhinometry: Methodological and clinical aspects.Allergy57(suppl 70): S5–S39, 2002.
18.
ChanK., HuangZ., and WangD.. Acoustic rhinometry assessment of nasal obstrution after treatment with fluticasone propionate in patients with perennial rhinitis.Aurius Nasus Laryngx30: 379–383, 2003.
19.
NielsenL., BjerkeT., ChristensenM.. Assessment of the allergic reaction in seasonal rhinitis: Acoustic rhinometry is a sensitive and objective method.Clin Exp Allergy26: 1268–1275, 1996.
20.
TahamilerR., YenerM., and CanakciogluS.. Efficacy of Odiosoft-Rhino in assessment of nasal obstruction: A comparative study with acoustic rhinometry after treatment with budesonide nasal spray in patients with perennial allergic rhinitis.Am J Rhinol21: 711–715, 2007.
21.
WilsonA., SimsE., OrrL.. An evaluation of short-term corticosteroid response in perennial allergic rhinitis using histamine and adenosine monophosphate nasal challenge.Br J Clin Pharmacol55: 354–359, 2003.
22.
WilsonA., SimsE., OrrL.. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis.Ann Allergy Asthma Immunol87: 344–349, 2001.
23.
QianW., ChenW., ChenJ., and HiaghtJ.. Acoustic rhinometry in preschool children.Otolaryngol Head Neck Surg137: 39–42, 2007.
24.
StraszekS., SchlünssenV., SigsgaardT., and PedersenO.. Reference values for acoustic rhinometry in decongested school children and adults: The most sensitive measurement for change in nasal patency.Rhinology45: 36–39, 2007.
25.
NathanR., EcclesR., HowarthP.. Objective monitoring of nasal patency and nasal physiology in rhinitis.J Allergy Clin Immunol115(suppl 3): S442–S459, 2005.
26.
WijkR.. Nasal hyperreactivity: Its pathogenesis and clinical significance.Clin Exp Allergy21: 661–667, 1991.
27.
TogiasA.. Unique mechanistic features of allergic rhinitis.J Allergy Clin Immunol105: S599–S604, 2000.
28.
GiannicoR., OliveiraC., SoléD., and NaspitzC.. Non-specific nasal provocation in children with allergic rhinitis.J Invest Allergol Clin Immunol6: 110–116, 1996.
29.
WijkR., and DiegesP.. Comparison of nasal responsiveness to histamine, methacholine and phentolamine in allergic rhinitis patients and controls.Clin Allergy17: 563–570, 1987.
30.
MullinsR., OlsonL., and SutherlandD.. Nasal histamine challenges in symptomatic allergic rhinitis.J Allergy Clin Immunol83: 955–959, 1989.
31.
BirchallM., HendersonJ., StudhamJ.. The effect of topical fluticasone propionate on intranasal histamine challenge in subjects with perennial allergic rhinitis.Clin Otolaryngol20: 204–210, 1995.
32.
SmallP., and BarrettD.. Effects of high doses of topical steroids on both ragweed and histamine-induced nasal provocation.Ann Allergy67: 520–524, 1991.
33.
CiprandiG., ToscaM., PassalacquaG., and CanonicaW.. Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge.Ann Allergy Asthma Immunol86: 433–438, 2001.
34.
PenagosM., CompalatiE., TarantiniF.. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials.Allergy61: 1280–1291, 2008.
35.
MeltzerE., BergerW., BerkowitzR.. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis.J Allergy Clin Immunol104: 107–114, 1999.
